Multicenter Phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma

Journal of Orthopaedic Science

Volumn 15, Issue 5, 2010, Pages 654-660

  Sugiura, Hideshi ^a   Fujiwara, Yasuhiro ^b   Ando, Masashi ^b   Kawai, Akira ^b   Ogose, Akira ^c   Ozaki, Toshifumi ^d   Yokoyama, Ryohei ^e   Hiruma, Toru ^f   Ishii, Takeshi ^g   Morioka, Hideo ^h   Mugishima, Hideo ⁱ  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NIIGATA UNIVERSITY   (Japan)

^d OKAYAMA UNIVERSITY   (Japan)

^e National Hospital Organization   (Japan)

^f KANAGAWA CANCER CENTER   (Japan)

^g CHIBA CANCER CENTER   (Japan)

^h KEIO UNIVERSITY   (Japan)

ⁱ NIHON UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEM CELL FACTOR;

ADOLESCENT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CHONDROSARCOMA; CHORDOMA; CLINICAL ARTICLE; CLINICAL TRIAL; DERMATOFIBROSARCOMA PROTUBERANS; DISEASE EXACERBATION; DISTANT METASTASIS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; EPITHELIOID SARCOMA; EWING SARCOMA; FATIGUE; FEMALE; FIBROSARCOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; LIPOSARCOMA; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MENTAL DISEASE; METASTASIS POTENTIAL; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; OSTEOSARCOMA; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RHABDOMYOSARCOMA; SARCOMA; SCHOOL CHILD; SYNOVIAL SARCOMA; TUMOR REGRESSION; TUMOR VOLUME; VOMITING;

EID: 78149452583     PISSN: 09492658     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00776-010-1506-9     Document Type: Article

References (30)

1. A. Jemal R. Siegel E. Ward Y. Hao J. Xu T. Murray, et al. 2008 Cancer statistics, 2008 CA Cancer J Clin 58 71 96 10.3322/CA.2007.0010 18287387 (Pubitemid 351521864)
2. G.D. Demetri A.D. Elias 1995 Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas: implications for decision making in the clinic Hematol Oncol Clin North Am 9 765 785 1:STN:280: DyaK28%2FhsFSqsQ%3D%3D 7490240
3. P. Lorigan J. Verweij Z. Papai S. Rodenhuis A. Le Cesne M.G. Leahy, et al. 2007 Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study J Clin Oncol 25 3144 3150 1:CAS:528:DC%2BD2sXptlGrt7k%3D 10.1200/JCO.2006.09.7717 17634494 (Pubitemid 47218064)
4. B.J. Druker S. Tamura E. Buchdunger S. Ohno G.M. Segal S. Fanning, et al. 1996 Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 2 561 566 1:CAS:528:DyaK28Xislyhs70%3D 10.1038/nm0596-561 8616716 (Pubitemid 26151518)
5. S.G. O'Brien F. Guilhot R.A. Larson I. Gathmann M. Baccarani F. Cervantes, et al. 2003 Imatinib compared with interferon and lowdose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 994 1004 10.1056/NEJMoa022457 12637609 (Pubitemid 36302244)
6. G.D. Demetri M. von Mehren C.D. Blanke A.D. Van den Abbeele B. Eisenberg P.J. Roberts, et al. 2002 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours N Engl J Med 347 472 480 1:CAS:528: DC%2BD38XmtV2nt7s%3D 10.1056/NEJMoa020461 12181401 (Pubitemid 34879334)
7. B.P. Rubin S.M. Schuetze J.F. Eary T.H. Norwood S. Mirza E.U. Conrad, et al. 2002 Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans J Clin Oncol 20 3586 3591 1:CAS:528:DC%2BD38XntVynsr8%3D 10.1200/JCO.2002.01.027 12202658 (Pubitemid 34983217)
8. E. Tamborini L. Bonadiman A. Greco A. Gronchi C. Riva R. Bertulli, et al. 2004 Expression of ligand-activated KIT and platelet derived growth factor receptor beta tyrosine kinase receptor in synovial sarcoma Clin Cancer Res 10 938 943 1:CAS:528:DC%2BD2cXhtFCnsL0%3D 10.1158/1078-0432.CCR-03-0059 14871970 (Pubitemid 38198893)
9. B.E. Smithey A.S. Pappo D.A. Hill 2002 C-kit expression in pediatric solid tumors: a comparative immunohistochemical study Am J Surg Pathol 26 486 492 10.1097/00000478-200204000-00011 11914627 (Pubitemid 34280122)
10. P.S. Cohen J.P. Chan M. Lipkunskaya J.L. Biedler R.C. Seeger 1994 Expression of stem cell factor and c-kit in human neuroblastoma: the Children's Cancer Group Blood 84 3465 3472 1:CAS:528:DyaK2MXitV2htbY%3D 7524740
11. I. González E.J. Andreu A. Panizo S. Inogés A. Fontalba J.L. Fernández-Luna, et al. 2004 Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis Clin Cancer Res 10 751 761 10.1158/1078-0432.CCR-0778-03 14760098 (Pubitemid 38174013)
12. I. Sulzbacher M. Träxler I. Mosberger S. Lang A. Chott 2000 Plateletderived growth factor-AA and -alpha receptor expression suggests an autocrine and/or paracrine loop in osteosarcoma Mod Pathol 13 632 637 1:STN:280:DC%2BD3cvmtVemtw%3D%3D 10.1038/modpathol.3880109 10874667
13. A. Abdiu S. Wingren S.E. Larsson A. Wasteson T.M. Walz 1999 Effects of human platelet-derived growth factor-AB on sarcoma growth in vitro and vivo Cancer Lett 141 39 45 1:CAS:528:DyaK1MXjs1Sjsb0%3D 10.1016/S0304-3835(99)00080-4 10454241 (Pubitemid 29261719)
14. Y. Oda B. Wehrmann K. Radig H. Walter I. Röse W. Neumann, et al. 1995 Expression of growth factors and their receptors in human osteosarcomas: immunohistochemical detection of epidermal growth factor, platelet-derived growth factor and their receptors: its correlation with proliferating activities and p53 expression Gen Diagn Pathol 141 97 103 1:STN:280:DyaK287ivFanuw%3D%3D 8548600
15. I. Sulzbacher P. Birner K. Trieb M. Träxler S. Lang A. Chott 2003 Expression of platelet derived growth factor AA is associated with tumor progression in osteosarcoma Mod Pathol 16 66 71 10.1097/01.MP.0000043522.76788. 0A 12527715 (Pubitemid 36152688)
16. K. Froberg R.E. Brown H. Gaylord C. Manivel 1999 Intraabdominal desmoplastic small round cell tumor: immunohistochemical evidence for up-regulation of autocrine and paracrine growth factors Ann Clin Lab Sci 29 78 85 1:STN:280:DyaK1M7ntlaltw%3D%3D 10074970
17. S.B. Lee K.A. Kolquist K. Nichols C. Englert S. Maheswaran M. Ladanyi, et al. 1997 The EWS-WT1 translocation product induces PDGFA in desmoplastic small round cell tumors Nat Genet 17 309 313 1:CAS:528:DyaK2sXntVSnuro%3D 10.1038/ng1197-309 9354795 (Pubitemid 27475994)
18. P.J. Zhang J.R. Goldblum B.R. Pawel T.L. Pasha C. Fisher F.G. Barr 2005 PDGF-A, PDGFR beta, TGFbeta3 and bone morphogenic protein 4 in desmoplastic small round cell tumors with EWS-WT1 gene fusion product and their role in stromal dysplasia: an immunohistochemical study Mod Pathol 18 382 387 1:CAS:528:DC%2BD2MXhtlertbs%3D 10.1038/modpathol.3800264 15389255 (Pubitemid 40395357)
19. C. Palman D.F. Bowen-Pope J.J. Brooks 1992 Platelet derived growth factor receptor (beta-subunit) immunoreactivity in soft tissue tumors Lab Invest 66 108 115 1:STN:280:DyaK387hsVCqsw%3D%3D 1309926
20. M.S. Merchant C.W. Woo C.L. Mackall C.J. Thiele 2002 Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity J Natl Cancer Inst 94 1673 1679 1:CAS:528:DC%2BD38Xpslequr8%3D 12441322
21. K. Beppu J. Jaboine M.S. Merchant C.L. Mackall C.J. Thiele 2004 Effect of Imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression J Natl Cancer Inst 96 46 55 1:CAS:528: DC%2BD2cXislarsg%3D%3D 10.1093/jnci/djh004 14709738
22. Enforcement Regulation No.106 of the Ministry of Health, Labor, and Welfare (revised GCP) dated May 15, 2003 (in Japanese).
23. The revised Pharmaceutical Affairs Act ("Kaisei Yakuji-hou") No. 96 of the Ministry of Health, Labor, and Welfare dated July 31, 2002 (in Japanese).
24. M. Bond M.L. Bernstein A. Pappo K.R. Schultz M. Krailo S.M. Blaney, et al. 2008 A Phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study Pediatr Blood Cancer 50 254 258 10.1002/pbc.21132 17262795
25. R. Chugh J.K. Wathen R.G. Maki R.S. Benjamin S.R. Patel P.A. Myers, et al. 2009 Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a Bayesian hierarchical statistical model J Clin Oncol 27 3148 3153 1:CAS:528:DC%2BD1MXhtFWitb3L 10.1200/JCO.2008.20.5054 19451433
26. M.C. Heinrich H. Joensuu G.D. Demetri C.L. Corless J. Apperley J.A. Fletcher, et al. 2008 Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases Clin Cancer Res 14 2717 2725 1:CAS:528:DC%2BD1cXlsV2qtbw%3D 10.1158/1078-0432.CCR-07-4575 18451237
27. S. Ugurel R. Hildenbrand A. Zimpfer P. La Rosée P. Paschka A. Sucker, et al. 2005 Lack of clinical efficacy of imatinib in metastatic melanoma Br J Cancer 92 1398 1405 1:CAS:528:DC%2BD2MXjsVSjtro%3D 10.1038/sj.bjc.6602529 15846297 (Pubitemid 40705006)
28. L.M. Krug J.P. Crapanzano C.G. Azzoli V.A. Miller N. Rizvi J. Gomez, et al. 2005 Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a Phase II clinical trial Cancer 103 2128 2131 1:CAS:528:DC%2BD2MXkslyltbw%3D 10.1002/cncr.21000 15812822 (Pubitemid 40605121)
29. S. Modi A.D. Seidman M. Dickler M. Moasser G. D'Andrea M.E. Moynahan, et al. 2005 A Phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer Breast Cancer Res Treat 90 157 163 1:CAS:528: DC%2BD2MXivVKhs7o%3D 10.1007/s10549-004-3974-0 15803362
30. F.M. Johnson L.M. Krug H.T. Tran S. Shoaf V.G. Prieto P. Tamboli, et al. 2006 Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma Cancer 106 366 374 1:CAS:528:DC%2BD28XjslOmu7k%3D 10.1002/cncr.21640 16342249 (Pubitemid 43100446)